Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AZD9592 + Bevacizumab + Fluorouracil + Leucovorin |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AZD9592 | AZD 9592|AZD-9592 | EGFR Antibody 74 MET Antibody 39 | AZD9592 is an antibody-drug conjugate (ADC) comprising a bispecific antibody that targets EGFR and MET conjugated to a topoisomerase 1 inhibitor, which potentially leads to tumor cell apoptosis and inhibition of tumor growth (Cancer Res (2023) 83 (7_Supplement): 5737, Cancer Res (2023) 83 (7_Supplement): 5736). | |
| Bevacizumab | Avastin | VEGF Antibody 17 VEGFR Inhibitor (Pan) 36 | Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov). | |
| Fluorouracil | Adrucil | 5-FU|5-Fluorouracil | Chemotherapy - Antimetabolite 14 | Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent that interferes with DNA and RNA synthesis, thereby preventing cancer cell growth (PMID: 28520376). Adrucil (fluorouracil) is FDA-approved for use in patients with adenocarcinoma of the colon, rectum, breast, stomach, and pancreas (FDA.gov). |
| Leucovorin | Wellcovorin | Calcium folinate|Calcium citrovorum factor|folinic acid | Chemotherapy - Antimetabolite 14 | Wellcovorin (leucovorin) is a metabolite of folate that enhances the efficacy of fluoruracil (PMID: 32490554). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05647122 | Phase I | AZD9592 + Bevacizumab + Fluorouracil + Leucovorin AZD9592 AZD9592 + Osimertinib | First in Human Study of AZD9592 in Solid Tumors (EGRET) | Recruiting | USA | ITA | FRA | ESP | CAN | AUS | 5 |